Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression.

Levels of full-length huntingtin (FL htt) influence organ and body weight, independent of polyglutamine length. The growth hormone-insulin like growth factor-1 (GH-IGF-1) axis is well established as a regulator of organ growth and body weight. In this study, we investigate the involvement of the IGF-1 pathway in mediating the effect of htt on body weight. IGF-1 expression was examined in transgenic mouse lines expressing different levels of FL wild-type (WT) htt (YAC18 mice), FL mutant htt (YAC128 and BACHD mice) and truncated mutant htt (shortstop mice). We demonstrate that htt influences body weight by modulating the IGF-1 pathway. Plasma IGF-1 levels correlate with body weight and htt levels in the transgenic YAC mice expressing human htt. The effect of htt on IGF-1 expression is independent of CAG size. No effect on body weight is observed in transgenic YAC mice expressing a truncated N-terminal htt fragment (shortstop), indicating that FL htt is required for the modulation of IGF-1 expression. Treatment with 17beta-estradiol (17beta-ED) lowers the levels of circulating IGF-1 in mammals. Treatment of YAC128 with 17beta-ED, but not placebo, reduces plasma IGF-1 levels and decreases the body weight of YAC128 animals to WT levels. Furthermore, given the ubiquitous expression of IGF-1 within the central nervous system, we also examined the impact of FL htt levels on IGF-1 expression in different regions of the brain, including the striatum, cerebellum of YAC18, YAC128 and littermate WT mice. We demonstrate that the levels of FL htt influence IGF-1 expression in striatal tissues. Our data identify a novel function for FL htt in influencing IGF-1 expression.

[1]  M. Aschner,et al.  Disease‐toxicant screen reveals a neuroprotective interaction between Huntington’s disease and manganese exposure , 2010, Journal of neurochemistry.

[2]  H. D. Rosas,et al.  Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease. , 2009, Analytical biochemistry.

[3]  J. Willey,et al.  PRESTROKE PHYSICAL ACTIVITY IS ASSOCIATED WITH SEVERITY AND LONG-TERM OUTCOME FROM FIRST-EVER STROKE , 2009, Neurology.

[4]  S. Harper Progress and challenges in RNA interference therapy for Huntington disease. , 2009, Archives of neurology.

[5]  P. Brundin,et al.  Beyond the brain: widespread pathology in Huntington's disease , 2009, The Lancet Neurology.

[6]  C. Bult,et al.  Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels , 2009, Aging cell.

[7]  I. Martins,et al.  Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  A. O’Sullivan,et al.  Short-term oral oestrogen therapy dissociates the growth hormone/insulin-like growth factor-I axis without altering energy metabolism in premenopausal women. , 2009, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[9]  Anne-Catherine Bachoud-Lévi,et al.  Neuroendocrine Disturbances in Huntington's Disease , 2009, PloS one.

[10]  G. Bonvento,et al.  Sustained effects of nonallele‐specific Huntingtin silencing , 2009, Annals of neurology.

[11]  Beate Sick,et al.  Dysregulation of Gene Expression in Primary Neuron Models of Huntington's Disease Shows That Polyglutamine-Related Effects on the Striatal Transcriptome May Not Be Dependent on Brain Circuitry , 2008, The Journal of Neuroscience.

[12]  Martin Drozda,et al.  Inhibitors of Cytochrome c Release with Therapeutic Potential for Huntington's Disease , 2008, The Journal of Neuroscience.

[13]  M. Hayden,et al.  Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. , 2008, Human molecular genetics.

[14]  Carlos Cepeda,et al.  Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD Mice , 2008, The Journal of Neuroscience.

[15]  J. Lüdemann,et al.  Reference ranges of serum IGF-1 and IGFBP-3 levels in a general adult population: results of the Study of Health in Pomerania (SHIP). , 2008, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[16]  K. G. Rajeev,et al.  Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits , 2007, Proceedings of the National Academy of Sciences.

[17]  Roger L Albin,et al.  Longitudinal Evaluation of the Hdh (CAG)150 Knock-In Murine Model of Huntington's Disease , 2007, The Journal of Neuroscience.

[18]  Alexandra Durr,et al.  Early Energy Deficit in Huntington Disease: Identification of a Plasma Biomarker Traceable during Disease Progression , 2007, PloS one.

[19]  S. Tabrizi,et al.  Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. , 2007, Journal of proteome research.

[20]  F. Walker Huntington's disease , 2007, The Lancet.

[21]  S. Humbert,et al.  Huntington’s disease: from huntingtin function and dysfunction to therapeutic strategies , 2006, Cellular and Molecular Life Sciences CMLS.

[22]  M. Hayden,et al.  Body weight is modulated by levels of full-length huntingtin. , 2006, Human molecular genetics.

[23]  L. Raymond,et al.  Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models , 2006, Neurobiology of Disease.

[24]  Elena Cattaneo,et al.  Normal huntingtin function: an alternative approach to Huntington's disease , 2005, Nature Reviews Neuroscience.

[25]  Magdalena Zernicka-Goetz,et al.  Cleavage pattern and emerging asymmetry of the mouse embryo , 2005, Nature Reviews Molecular Cell Biology.

[26]  I. Kanazawa,et al.  Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA , 2005, Neuroscience Research.

[27]  R. Mandel,et al.  Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  M. Hayden,et al.  Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Sarah J Tabrizi,et al.  Gene expression in Huntington's disease skeletal muscle: a potential biomarker. , 2005, Human molecular genetics.

[30]  M. Hayden,et al.  Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. , 2005, Human molecular genetics.

[31]  H. Paulson,et al.  RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  O. Gavrilova,et al.  Studies involving the GH-IGF axis: Lessons from IGF-I and IGF-I receptor gene targeting mouse models. , 2005, Journal of endocrinological investigation.

[33]  Fabrice P Cordelières,et al.  Huntingtin Controls Neurotrophic Support and Survival of Neurons by Enhancing BDNF Vesicular Transport along Microtubules , 2004, Cell.

[34]  A. Ochoa,et al.  Assessment of the nutrition status of patients with Huntington's disease. , 2004, Nutrition.

[35]  B. Seed,et al.  A PCR primer bank for quantitative gene expression analysis. , 2003, Nucleic acids research.

[36]  Martin Drozda,et al.  Depletion of wild‐type huntingtin in mouse models of neurologic diseases , 2003, Journal of neurochemistry.

[37]  Andrea Crotti,et al.  Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes , 2003, Nature Genetics.

[38]  E. Simpson,et al.  Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. , 2003, Human molecular genetics.

[39]  Charles Kooperberg,et al.  Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. , 2002, Human molecular genetics.

[40]  J. Olson,et al.  Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. , 2002, Human molecular genetics.

[41]  D. Rubinsztein Lessons from animal models of Huntington's disease. , 2002, Trends in genetics : TIG.

[42]  L. Raymond,et al.  Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease , 2002, Neuron.

[43]  Manjit,et al.  Neurology , 1912, NeuroImage.

[44]  J. Olson,et al.  Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. , 2002, Human molecular genetics.

[45]  M. MacDonald,et al.  The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. , 2001, Human molecular genetics.

[46]  A. Reiner,et al.  Neurons Lacking Huntingtin Differentially Colonize Brain and Survive in Chimeric Mice , 2001, The Journal of Neuroscience.

[47]  Blair R. Leavitt,et al.  Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease , 2001, Science.

[48]  R. Albin,et al.  Neurological abnormalities in a knock-in mouse model of Huntington's disease. , 2001, Human molecular genetics.

[49]  M. MacDonald,et al.  Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. , 2000, Human molecular genetics.

[50]  Michael S. Levine,et al.  Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice , 2000, Nature Genetics.

[51]  René Hen,et al.  Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease , 2000, Cell.

[52]  Claire-Anne Gutekunst,et al.  A YAC Mouse Model for Huntington’s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration , 1999, Neuron.

[53]  D. Borchelt,et al.  Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. , 1999, Human molecular genetics.

[54]  C. Roberts,et al.  The IGF system : molecular biology, physiology, and clinical applications , 1999 .

[55]  J. Hodgson,et al.  Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype. , 1996, Human molecular genetics.

[56]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[57]  James F. Gusella,et al.  Differential Expression of Normal and Mutant Huntington's Disease Gene Alleles , 1996, Neurobiology of Disease.

[58]  Y. Agid,et al.  Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias , 1995, Nature.

[59]  S. Hersch,et al.  Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[60]  C. Ross,et al.  Expression of the Huntington's disease (IT15) protein product in HD patients. , 1995, Human molecular genetics.

[61]  E. Hirsch,et al.  Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form , 1995, Nature Genetics.

[62]  I. Kanazawa,et al.  Abnormal gene product identified in Huntington's disease lymphocytes and brain. , 1995, Biochemical and biophysical research communications.

[63]  C. Rosen,et al.  Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[64]  Peter S. Harper,et al.  Huntington's disease , 1991 .

[65]  R. Hochberg,et al.  A simple and sensitive microtiter plate estrogen bioassay based on stimulation of alkaline phosphatase in Ishikawa cells: estrogenic action of delta 5 adrenal steroids. , 1990, Endocrinology.

[66]  L. M. Morales,et al.  Nutritional evaluation of Huntington disease patients. , 1989, The American journal of clinical nutrition.

[67]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[68]  C. Tamminga,et al.  Twenty-four hour plasma levels of growth hormone and prolactin in Huntington's disease. , 1983, Journal of neurology, neurosurgery, and psychiatry.

[69]  M. Molitch,et al.  Human growth hormone and somatomedin C suppress the spontaneous release of growth hormone in unanesthetized rats. , 1983, Endocrinology.

[70]  C. Tamminga,et al.  Plasma growth hormone and prolactin response to dopaminergic GABAmimetic and cholinergic stimulation in Huntington's disease , 1983, Neurology.

[71]  I. Bone,et al.  Studies of hypothalamic function in Huntington's chorea. , 1981, Journal of neurology, neurosurgery, and psychiatry.

[72]  E. Parati,et al.  Growth hormone hyperresponsiveness to dopaminergic stimulation in Huntington's chorea. , 1979, Neuroendocrinology.

[73]  W. Tourtellotte,et al.  Growth hormone and prolactin secretion in Huntington's disease. , 1979, Life sciences.

[74]  D. Cocchi,et al.  Altered growth hormone and prolactin responses to dopaminergic stimulation in Huntington's chorea. , 1977, The Journal of clinical endocrinology and metabolism.

[75]  O. Phillipson,et al.  Plasma growth hormone concentrations in Huntington's chorea. , 1976, Clinical science and molecular medicine.

[76]  W. R. Sulaiman,et al.  Altered growth hormone release in Huntington's chorea. , 1976, Journal of neurology, neurosurgery, and psychiatry.